Arcturus Therapeutics. has filed a patent for compounds of Formula (I) and their pharmaceutically acceptable salts. The compounds have various substituents and can be used in pharmaceutical applications. GlobalData’s report on Arcturus Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcturus Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Arcturus Therapeutics's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230295081A1) describes a compound of Formula I and its pharmaceutically acceptable salts. The compound has various structural features, including substituents and linkers, that are defined in the claims. The compound can be used in the development of pharmaceutical compositions for the treatment of diseases.
The compound of Formula I has different possible variations for R1 and R2, which can be either H or C1-6 alkyl, or they can be joined to form a saturated heterocyclic ring. The compound also includes a linear C1-4 alkylene for R1 and a group —(CH2)m(X)n— for R2, where X can be O, S, or NR9 (where R9 is H or C1-6 alkyl), m can be 1, 2, 3, or 4, and n can be 0 or 1. The compound further includes a linear C1-6 alkylene (L1) that may be substituted with up to three methyl groups. The compound also contains a group Y, which can have various structures defined in the claims.
The claims further specify the possible variations for R3, R4, R5, R6, R7, and R8, which can be different types of alkyl groups, monocycloalkyl groups, bicycloalkyl groups, or aryl groups. These groups can be substituted with various substituents, such as alkyl, alkoxy, and -F. The claims also define the possible variations for L2, L3, L4, L5, L6, L7, L8, and L9, which are alkylene groups that may or may not be present in the compound.
The patent also describes the use of the compound in lipid compositions, particularly for delivering nucleic acids. The lipid compositions can include siRNA, mRNA, self-replicating RNA, DNA plasmids, or antisense oligonucleotides. The lipid compositions can be in the form of liposomes, lipoplexes, or lipid nanoparticles. The patent also covers pharmaceutical compositions containing the lipid nanoparticles and a pharmaceutically acceptable excipient. These compositions can be used for the treatment of diseases or for expressing proteins or polypeptides in target cells.
In summary, the filed patent describes a compound of Formula I and its various structural variations, as well as its use in lipid compositions for delivering nucleic acids. The patent covers the development of pharmaceutical compositions for the treatment of diseases and the expression of proteins or polypeptides in target cells.
To know more about GlobalData’s detailed insights on Arcturus Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
